Postmenopausal osteoporosis in the dialysis patient

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 4, 2003, Pages 381-386

  Weisinger, Jose R ^a   Bellorin Font, Ezequiel ^a  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

Author keywords

Bisphosphonates; Bone mineral density; Hemodialysis; Hormone replacement therapy; Osteoporosis; SERM

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR;

AMENORRHEA; BONE DISEASE; BONE MASS; BONE TURNOVER; EARLY MENOPAUSE; ESTROGEN DEFICIENCY; FEMALE; HEMODIALYSIS PATIENT; HORMONE SUBSTITUTION; HUMAN; KIDNEY FAILURE; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR;

BONE DENSITY; CLINICAL TRIALS; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 0038779808     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200307000-00006     Document Type: Review

References (51)

1. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17:2094-2105. This is an excellent review of emerging advances in the pathophysiology and treatment of renal osteodystrophy.
2. Lindberg JS, Moe SM. Osteoporosis in end stage renal disease. Semin Nephrol 1999; 19:115-122.
3. United States Renal Data System. USRDS 2002 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Renal Diseases; 2002.
4. Mazzuchi N, González-Martínez, Schwedt E, et al. Incidence and prevalence of the treatment of end stage renal disease in Latin America. Nefrología Latinoamericana 1999; 6:154-159.
5. Cummings S, Nevitt M, Browner W, et al. Risk factors for hip fracture in white women: study of osteoporotic fractures research group. N Engl J Med 1995; 332:767-773.
6. Mussolino M, Looker A, Madans J, et al. Risk factors for hip fractures in white men: the NHANES I epidemiologic follow-up study. J Bone Miner Res 1998; 13:918-924.
7. Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33:287-293.
8. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396-399.
9. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288:3014-3018.
10. Hodsman AB. Fragility fractures in dialysis and transplant patients: is it osteoporosis, and how should it be treated? Perit Dial Int 2001; 21 (Suppl 3):S247-S255.
11. Fontaine MA, Albert A, Dubois B, et al. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000; 54:218-226.
12. Jamal SA, Chase C, Goh YI, et al. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 2002; 39:843-849.
13. Hsu C, Cummings SR, McCulloch CE, Chertow GM. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int 2002; 61:1814-1820. This controversial epidemiological study challenges the concept that bone mineral density is affected early in renal failure. The study suggests that even though subjects with worse renal function have lower BMD, this association is explained by confounding, principally by sex, age and weight. Thus, renal function itself does not seem to be independently associated with BMD.
14. Kaji H, Suzuki M, Yano S, et al. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 2002; 22:325-331.
15. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2002; 36:1115-1121.
16. Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:2200-2205.
17. Lim VS, Henriquez C, Sieversten G, Frohman LA. Ovarian function in chronic renal failure: evidence of hypothalamic anovulation. Ann Intern Med 1980; 92:21-27.
18. Cochrane R, Regan L. Undetected gynecological disorders in women with renal disease. Hum Reprod 1997; 12:667-670.
19. Holley JL, Schmidt RJ, Bender FH, et al. Gynecological and reproductive issues in women on dialysis. Am J Kidney Dis 1997; 29:685-690.
20. Stehman-Breen CO, Gillen D, Gipson D. Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int 1999; 56:2243-2247.
21. Collins KS, Schoen C, Joseph S, et al. Health concerns across a woman's lifespan: The Commonwealth Fund 1998 Survey of Women's Health. New York: The Commonwealth Fund; 1999.
22. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG 2002; 109:1319-1330.
23. Jang C, Bell RJ, White VS, et al. Women health issues in hemodialysis patients. Med J Aust 2001; 175:298-301.
24. Weisinger JR. Role of hormone replacement in the management of osteoporosis in hemodialyzed women: perspectives for the future. Nephrol Dial Transplant 2000; 15 (Suppl 5); 36-37.
25. Holley JL, Schmidt RJ. Hormone replacement therapy in postmenopausal women with end stage renal disease: a review of the issues. Semin Dial 2001; 14:146-149.
26. Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and anovulatory disturbances. N Eng J Med 1990; 323:1221-1227.
27. Schachter M, Shoham Z. Amenorrhea during the reproductive years: is it safe? Fertil Steril 1994; 62:1-16.
28. Weisinger JR, Gonzalez L, Alvarez H, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 2000; 58:331-335.
29. Horowitz M. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993; 260:626-627.
30. Manolagas S. Birth and death of bone cells: basic regulatory mechanisms and implications for pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.
31. Pereira BJ, Shapiro L, King AJ, et al. Plasma levels of IL-1beta, TNF-alpha, and other specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis. Kidney Int 1994; 45:890-896.
32. Naveh-Many T, Almogi G, Livni N, Silver J. Estrogen receptors, and biologic response in rat parathyroid tissue and C-cells. J Clin Invest 1992; 90:2434-2438.
33. Kanatani M, Sugimoto T, Takahashi Y, et al. Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J Bone Miner Res 1998; 13:854-862.
34. Ginsburg ES, Owen Jr WF, Greenberg L, et al. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 1996; 81:4414-4417.
35. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 1999; 14:1238-1243.
36. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288:321-333. The Women's Health Initiative study focused on defining the risks and benefits of combined estrogen plus progestin in postmenopausal women with uterus. The astonishing and still controversial results of this study, which included over 160 000 women, have changed dramatically the decision-making process regarding HRT prescription in postmenopausal women. The results indicate that HRT should not be initiated or continued for primary prevention therapy of coronary heart disease.
37. Clarkson TB. Raloxifene revisited. Fertil Steril 2002; 77:445-447.
38. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645.
39. Barrett-Connor E, Grady D, Sashegyi A, et al. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial. JAMA 2001; 287:847-857.
40. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606-1615.
41. Hernández E, Valera R, Alonzo E, et al. Effect of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int (in press).
42. Weisinger JR, Pfeferman-Heilberg I, Hernandez E, et al. Selective estrogen receptor modulators in chronic renal failure. Kidney Int (in press).
43. Timmer CJ, Doorstam D. Effect of renal impairment on the phatmacokinetics of a single oral dose of tibolone 2.5 mg in early postmenopausal women. Pharmacotherapy 2002; 22:148-153.
44. Strauss SE. Herbal medicines: what's in the bottle? N Engl J Med 2002; 347:1997-1998.
45. Velazquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal protection. Am J Kidney Dis 2001; 37:1056-1068.
46. Ranich T, Bhathena SJ, Velazquez MT. Protective effects of dietary phytoestrogens in chronic renal disease. J Renal Nutr 2001; 11:183-193.
47. Roemheld-Hamm B, Dahl NV. Herbs, menopause and dialysis. Semin Dial 2002; 15:53-59.
48. Ala-Houhala I, Saha H, Liukko-Sipi S, et al. Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant 1999; 14:699-705.
49. Bergner R, Dill K, Boerner D, Uppenkamp M. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002; 17:1281-1285. This was a well designed pharmacological study that evaluated the dialysis removal of ibandronate, a potent bisphosphonate. The drug was efficiently removed by hemodialysis.
50. Saha H, Ala-Houhala I, Ylitalo P, et al. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients. Clin Nephrol 2002; 58:47-53. The study demonstrated that skeletal deposition of the bisphosphonate clodronate is related to bone turnover and that significant binding of the drug occurs in cases of low bone turnover. This should caution the practicing physician on the prescription of these drugs in ESRD.
51. Khosla S, Melton III LJ, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87:1443-1450. This excellent review evaluates the supporting evidence of multiple lines of investigation suggesting that estrogen plays a major, and likely dominant, role in regulating bone metabolism in men.